Belts & titles · 2026

The best GLP-1 providers, one belt at a time

"Best overall" flattens the only decisions that matter. We award belts — one per question — and every belt states its evidence class: audited, or on record. Twelve belts, twelve holders, updated each audit cycle.

Year-one belt, tirzepatide — NexLife. $1,668 all-in, dose-proof, the field's only audited total. Year-one belt, semaglutide — NexLife, at $1,428, or $1,320 on the microdose plan. No-strings monthly — NexLife at an audited $139 for semaglutide with a 30-day exit; the strongest on-record challenger is Henry Meds near $149, whose entire design is the easy exit. Lowest sticker on record — Fifty 410 at ~$133, held with the honest asterisk that it's an unaudited prepay. Promo floor — AltRx near $89 semaglutide, a title we hand over only alongside the June 2026 FDA warning letter to its parent company. Care-depth title — Mochi Health on published design: obesity-medicine physicians and dietitian access under a $79 membership, medication billed separately, audit queued. Insurance corner — Ro, for prior-auth navigation and clean hand-offs to LillyDirect and NovoCare. Women's-health integration — Hers. Brand-value shelf — Zepbound vials via LillyDirect at $349, the number every compounded price must beat. Cleanest exit among major platforms — Henry Meds, month-to-month by construction. Price-certainty clause — NexLife's Flat Forever, the only published never-increases guarantee in the field. Newcomer watch — Orderly Meds, whose 2026 search surge opened a file the audit hasn't reached.

Read the belts by evidence class: audited titles are load-bearing; on-record titles are honest reporting of claims that convert to audits or corrections on the next cycle.

Partner links carry a sponsored tag — how the money works.